Advanced Therapy Medicinal Products Market To Record A Sluggish CAGR of 17.4% By 2026 | Grand View Research, Inc.

May 09 08:22 2020
Advanced Therapy Medicinal Products Market To Record A Sluggish CAGR of 17.4% By 2026 | Grand View Research, Inc.

Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research,The global advanced therapy medicinal products market size is expected to reach USD 9.6 billion by 2026.

According to a report, “Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (Cell, CAR-T, Gene Therapy, Stem Cell, Non-stem Cell), By Region, And Segment Forecasts, 2020 – 2026”, published by Grand View Research, Inc.,The global advanced therapy medicinal products market size is expected to reach USD 9.6 billion by 2026, expanding at a CAGR of 17.4% over the forecast period, according to a new report published by Grand View Research, Inc. The use of advanced therapy medicinal products (ATMPs) is well-proven for the improvement in the quality of life and health status in the long run for patients suffering from life-threatening conditions. This is particularly for diseases with few or no alternative treatment options. These novel treatment modes deliver transformative advantages not offered by conventional forms of disease treatment, thereby driving the ATMP market.

In the current scenario, ATMPs are expensive for patients as well as health insurance schemes. Growing competition to gain revenue share could help reduce prices and improve the affordability, along with the acceptance of these products as mainstream medicine. Furthermore, manufacturers are embracing efforts to streamline technology and logistics for the provision of therapies at accessible prices.

Moreover, lack of manufacturing capabilities to meet growing consumer demand coupled with the resource and budget constraints faced by advanced therapy medicinal product developers has created lucrative avenues for contract services providers and has intensified the market competition. This has led to a rise in market activities by contract service providers. For instance, in November 2019, Fujifilm Diosynth established a 60,000-square-feet Gene Therapy Innovation Center to offer downstream, upstream, and analytical services.

“Would you Like/Try a Sample Report”

China advanced therapy medicinal products (ATMP) market

Further key findings from the report suggest:

  • Cell therapies dominated the ATMP market in 2019, owing to the presence of a substantially high number of approved products for clinical use

  • Huge investments by commercial and non-commercial sponsors in the testing of cell-based product candidates in clinical studies has also spurred the revenue share of cell therapies

  • Stem cell-based therapies accounted for the major revenue share in 2019, owing to the high adoption of hematopoietic stem cell transplantation for the treatment of immune system and blood disorders

  • The recent FDA approval of Zolgensma gene therapy product in May 2019 has accelerated R&D activities in the gene therapy arena, this is anticipated to drive the segment growth at lucrative pace

  • Similarly, CAR-T therapy is projected to expand at a significant CAGR during the forecast period, resulted by the approval such as Kymriah and Yescarta in the past years

  • With a high number of approvals of therapies, North America, particularly U.S., captured the largest revenue share in 2019. Increasing marketing operations to sustain the growing market competition coupled with the presence of a relatively high number of candidates in the pipeline is anticipated to propel the U.S. market at a lucrative CAGR in the forthcoming years

  • Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; Celgene Corporation; and Gilead Lifesciences, Inc. are some major revenue-generating companies operating in the advanced therapy medicinal product market

  • High prices of existing products and technological advancements in genetic tools have driven the entry of new players in the market

Therapy Type Insights

Over the past few years, there has been a notable increase in the clinical development of advanced therapies, including gene therapies, cell therapies, and tissue engineering products. Several products have already secured approval in U.S., China, Europe, South Korea, Japan, Australia, Canada, India, and New Zealand. As a result, a substantial number of well-established as well as start-up pharma companies, universities, and hospitals are shifting their focus from conventional therapies to advanced therapies.

Cell therapies held the largest revenue share of the advanced therapy medicinal products market in 2019. Increased funding from governments as well as private organizations to support cell therapy clinical trials, improving the legal framework for cell therapy manufacturing and implementation, and proven efficacy of products are some of the key drivers for the growth of the segment.

Global advanced therapy medicinal products (ATMP) market

Based on cell types, stem cell therapies held the dominant revenue share in 2019 owing to the presence of a substantial number of approved therapies. The entry of new players such as Celularity, Rubius Therapeutics, Century Therapeutics, Fate Therapeutics, ViaCyte, Magenta Therapeutics, ReNeuron, Promethera Biosciences, Frequency Therapeutics, and Cellular Dynamics in the recent years reflects the expanding stem cells business operations.

Have Any Query? Ask Our Experts for More Details on Report:

Currently, the number of approved gene therapy is limited, however, a substantial number of products is anticipated to receive regulatory approvals in the forthcoming years. Growing R&D activities in gene therapy trials have resulted in an increase in market activities by the key stakeholders operating in the ATMP market. For instance, in April 2019, Catalent announced to acquire Paragon Bioservices to expand its business footprint in the gene therapy arena.

Grand View Research has segmented the global advanced therapy medicinal products market on the basis of therapy type and region:

Advanced Therapy Medicinal Products Therapy Type Outlook (Revenue, USD Million, 2015 – 2026)

  • Cell Therapy

    • Stem Cell Therapy

    • Non-stem Cell Therapy

  • Gene Therapy

  • CAR-T Therapy

  • Tissue Engineered Product

Advanced Therapy Medicinal Products Regional Outlook (Revenue, USD Million, 2015 – 2026)

  • North America

    • U.S.

    • Canada

  • Europe

  • Asia Pacific

    • China

    • Japan

  • Rest of World

Request for Customization :

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States